The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study-Reference-Cited by-全球学者库

登录注册会员服务联系我们

The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study

Published:2022-09-03 Issue:3 Volume:72 Page:783-794
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Li Chongwu,Wu Junqi,Jiang Long,Zhang Lei,Huang Jia,Tian Yu,Zhao Yue,Liu Xiucheng,Xia Lang,E Haoran,Gao Peigen,Hou Likun,Yang Minglei,Ma Minjie,Su Chunxia,Zhang Hao,Chen Hezhong,She Yunlang,Xie Dong,Luo Qingquan,Chen Chang

Funder

National Natural Science Foundation of China

Science Foundation of Shanghai

Clinical Research Foundation of Shanghai Pulmonary Hospital

Shanghai Municipal Health Commission

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

https://link.springer.com/content/pdf/10.1007/s00262-022-03262-w.pdf

Reference40 articles.

1. Gandhi L, Rodríguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 378(22):2078–2092

2. Forde PM, Chaft JE, Smith KN et al (2018) Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med 378(21):1976–1986

3. Shu CA, Gainor JF, Awad MM et al (2020) Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 21(6):786–795

4. Provencio M, Nadal E, Insa A et al (2020) Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 21(11):1413–1422

5. Jiang L, Huang J, Jiang S et al (2021) The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer. Cancer Immunol Immunother 70(8):2313–2321

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive value of peripheral blood biomarkers in patients with non-small-cell lung cancer responding to anti-PD-1-based treatment;Cancer Immunology, Immunotherapy;2024-01

2. Association of systemic inflammatory markers and tertiary lymphoid structure with pathological complete response in gastric cancer patients receiving preoperative treatment: a retrospective cohort study;International Journal of Surgery;2023-09-21

3. Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non‐small cell lung cancer patients with neoadjuvant immunotherapy;Cancer Science;2023-09-20

4. Variation of Peripheral Blood-based Biomarkers for Response of Anti-PD-1 Immunotherapy in Lung Cancer;2023-08-30

5. Immunotherapy for early-stage non-small cell lung cancer: A system review;Journal of Cancer Research and Therapeutics;2023-08

全球学者库

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"全球学者库"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前全球学者库共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2023 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3